The present invention discloses an improved nanoemulsion comprising a uniformand discrete range of very small particle nano-sized diameters. This uniformityresults in improved bioavailability of incorporated compounds (i.e., pharmaceuticalsor nutraceuticals) as reflected in various pharmacokinetic parameters including,but not limited to, decreased Tmax, increased Cmax, and increased AUC. The improvedmethod of making these uniform nanoemulsions utilizes microfluidization whichdiffers in both process and mechanics when compared to conventional millingand grinding techniques used to generate nanoparticulate compositions. Further,the improvement results, in part, from a novel step of mixing a substantiallysoluble compound into a heated dispersion medium. This is unlike current nanoparticulatecomposition methods that mix an insoluble compound with an unheated dispersionmedium. Further, these nanoemulsions are observed to be bacterial-resistantand stable to extremes in both temperature and pH changes. Consequently, thesenanoemulsions are expected to have a significantly prolonged shelf-life thancurrently available nanoemulsions.
